MediWound Ltd. (NASDAQ:MDWD) Given Consensus Recommendation of “Moderate Buy” by Analysts

MediWound Ltd. (NASDAQ:MDWD) has earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $33.50.

A number of analysts have weighed in on MDWD shares. Wall Street Zen raised MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 price target (up previously from $31.00) on shares of MediWound in a research report on Friday, November 21st.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the period. Russell Investments Group Ltd. increased its position in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the period. Rhumbline Advisers lifted its holdings in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 481 shares during the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in shares of MediWound in the third quarter valued at approximately $180,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Stock Performance

Shares of MediWound stock opened at $16.25 on Friday. The firm has a market cap of $180.21 million, a PE ratio of -8.55 and a beta of 0.07. The firm’s 50-day simple moving average is $18.23 and its 200-day simple moving average is $18.32. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.57. The firm had revenue of $5.43 million for the quarter, compared to analyst estimates of $6.56 million. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. On average, equities analysts predict that MediWound will post -2.66 earnings per share for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.